ArticleThe Journal of pharmacology and experimental therapeutics2016
Stratification of Cannabinoid 1 Receptor (CB1R) Agonist Efficacy: Manipulation of CB1R Density through Use of Transgenic Mice Reveals Congruence between In Vivo and In Vitro Assays.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- A critical assessment of the abuse, dependence and associated safety risks of naturally occurring and synthetic cannabinoids.Frontiers in psychiatry · 2024Review
- The synthetic cannabinoid 5F-MDMB-PICA enhances the metabolic activity and angiogenesis in human brain microvascular endothelial cells by upregulation of VEGF, ANG-1, and ANG-2.Toxicology research · 2023Article
- In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.Pharmacology, biochemistry, and behavior · 2022Article
- Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9-tetrahydrocannabinol (ΔPsychopharmacology · 2022Article
- Medicinal Cannabis and Central Nervous System Disorders.Frontiers in pharmacology · 2022Review
- Computational Approach Reveals Pronociceptive Potential of Cannabidiol in Osteoarthritis: Role of Transient Receptor Potential Channels.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications.Life (Basel, Switzerland) · 2021Review
- Behavioral Battery for Testing Candidate Analgesics in Mice. II. Effects of Endocannabinoid Catabolic Enzyme Inhibitors and ∆9-Tetrahydrocannabinol.The Journal of pharmacology and experimental therapeutics · 2021Article
- Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and Cannabinoids.The Journal of pharmacology and experimental therapeutics · 2021Article
- Astroglial CB1 Cannabinoid Receptors Mediate CP 55,940-Induced Conditioned Place Aversion Through Cyclooxygenase-2 Signaling in Mice.Frontiers in cellular neuroscience · 2021Article
- The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice.Drug and alcohol dependence · 2020Article
- In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.Pharmacology, biochemistry, and behavior · 2020Article
- Molecular Mechanism and Cannabinoid Pharmacology.Handbook of experimental pharmacology · 2020Article
- Disruption of an enhancer associated with addictive behaviour within the cannabinoid receptor-1 gene suggests a possible role in alcohol intake, cannabinoid response and anxiety-related behaviour.Psychoneuroendocrinology · 2019Article
- Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.Neuropharmacology · 2018Article
- Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.The Journal of pharmacology and experimental therapeutics · 2018Article
- Molecular Understanding of the Activation of CB1 and Blockade of TRPV1 Receptors: Implications for Novel Treatment Strategies in Osteoarthritis.International journal of molecular sciences · 2018Article
- Gender-specific association of functionalNeuropsychiatric disease and treatment · 2018Article
- Medications for substance use disorders (SUD): emerging approaches.Expert opinion on emerging drugs · 2017Review
- Apparent CBThe Journal of pharmacology and experimental therapeutics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
T W GrimVirginia Commonwealth University-Pharmacology and Toxicology, Richmond, Virginia (T.W.G., A.J.M., M.M.G., L.J.S.-S., D.E.S., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (J.L.W., B.F.T.); Cayman Chemical, Ann Arbor, Michigan (G.W.E.) grimtw@vcu.edu.
A J MoralesVirginia Commonwealth University-Pharmacology and Toxicology, Richmond, Virginia (T.W.G., A.J.M., M.M.G., L.J.S.-S., D.E.S., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (J.L.W., B.F.T.); Cayman Chemical, Ann Arbor, Michigan (G.W.E.).
M M GonekVirginia Commonwealth University-Pharmacology and Toxicology, Richmond, Virginia (T.W.G., A.J.M., M.M.G., L.J.S.-S., D.E.S., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (J.L.W., B.F.T.); Cayman Chemical, Ann Arbor, Michigan (G.W.E.).
J L WileyVirginia Commonwealth University-Pharmacology and Toxicology, Richmond, Virginia (T.W.G., A.J.M., M.M.G., L.J.S.-S., D.E.S., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (J.L.W., B.F.T.); Cayman Chemical, Ann Arbor, Michigan (G.W.E.).
B F ThomasVirginia Commonwealth University-Pharmacology and Toxicology, Richmond, Virginia (T.W.G., A.J.M., M.M.G., L.J.S.-S., D.E.S., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (J.L.W., B.F.T.); Cayman Chemical, Ann Arbor, Michigan (G.W.E.).
G W EndresVirginia Commonwealth University-Pharmacology and Toxicology, Richmond, Virginia (T.W.G., A.J.M., M.M.G., L.J.S.-S., D.E.S., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (J.L.W., B.F.T.); Cayman Chemical, Ann Arbor, Michigan (G.W.E.).
L J Sim-SelleyVirginia Commonwealth University-Pharmacology and Toxicology, Richmond, Virginia (T.W.G., A.J.M., M.M.G., L.J.S.-S., D.E.S., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (J.L.W., B.F.T.); Cayman Chemical, Ann Arbor, Michigan (G.W.E.).
D E SelleyVirginia Commonwealth University-Pharmacology and Toxicology, Richmond, Virginia (T.W.G., A.J.M., M.M.G., L.J.S.-S., D.E.S., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (J.L.W., B.F.T.); Cayman Chemical, Ann Arbor, Michigan (G.W.E.).
S S NegusVirginia Commonwealth University-Pharmacology and Toxicology, Richmond, Virginia (T.W.G., A.J.M., M.M.G., L.J.S.-S., D.E.S., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (J.L.W., B.F.T.); Cayman Chemical, Ann Arbor, Michigan (G.W.E.).
A H LichtmanVirginia Commonwealth University-Pharmacology and Toxicology, Richmond, Virginia (T.W.G., A.J.M., M.M.G., L.J.S.-S., D.E.S., S.S.N., A.H.L.); RTI International, Research Triangle Park, North Carolina (J.L.W., B.F.T.); Cayman Chemical, Ann Arbor, Michigan (G.W.E.).
RTI International · USVirginia Commonwealth University · US
Funding
TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7MVCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI YAN ZHANG · 2014 to 2026
$13.8MTHC RECEPTORSR01DA003672 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI WILEY, JENNY L. · 1985 to 2018
$4.9MInvestigation of Synthetic Cannabinoid Exposures and Pharmacological ConsequencesR01DA040460 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI RANGAN MAITRA, Yanan Zhang · 2016 to 2026
$4.5MEndocannabinoid modulation of pain-depressed behaviorR01DA030404 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S, SIM-SELLEY, LAURA J · 2011 to 2020
$3.7MMonoacylglycerol Lipase Inhibitors for Treating Opioid Use Disorders (RO)R01DA032933 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F, LICHTMAN, ARON H · 2012 to 2014
$1.5MNIDA NIH HHS P30 DA033934NIDA NIH HHS R01 DA003672NIDA NIH HHS R01 DA030404NIDA NIH HHS R01 DA032933NIDA NIH HHS R01 DA040460NIDA NIH HHS T32 DA007027
Abstract
Synthetic cannabinoids (SCs) are an emerging class of abused drugs that differ from each other and the phytocannabinoid ∆
Indexed as
AnimalsCannabinoidsDrug Evaluation, PreclinicalFemaleGuanosine 5'-O-(3-Thiotriphosphate)MaleMiceMice, TransgenicReceptor, Cannabinoid, CB1CannabinoidsGuanosine 5'-O-(3-Thiotriphosphate)Receptor, Cannabinoid, CB1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.